Characterizing Vericiguat Treatment in Heart Failure: A Multicenter Real-World Study in China

被引:0
作者
Wang, Qi [1 ]
Wang, Guangchuan [2 ]
Peng, Jiecheng [3 ]
Li, Jingjing [4 ]
Ju, Changlin [5 ]
Pan, Lingxin [6 ]
Xu, Zhiwei [7 ]
Qian, Jun [8 ]
Liu, Zhiquan [1 ]
Wu, Guohong [1 ]
Wei, Xueping [1 ]
Yan, Ji [1 ]
Xiang, Xuejun [9 ]
Chen, Kangyu [1 ]
HCDCG
机构
[1] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Cardiol, Div Life Sci & Med, Hefei 230001, Anhui, Peoples R China
[2] Huaibei Peoples Hosp, Dept Cardiol, Huaibei 235000, Anhui, Peoples R China
[3] Anhui Med Univ, Dept Cardiol, Peoples Hosp Anqing Affiliated 1, Anqing 246004, Anhui, Peoples R China
[4] Third Peoples Hosp Bengbu, Dept Cardiol, Bengbu 233000, Anhui, Peoples R China
[5] Wannan Med Coll, Dept Cardiol, Affiliated Hosp 1, Wuhu 241001, Anhui, Peoples R China
[6] Peoples Hosp Tongling, Dept Cardiol, Tongling 244000, Anhui, Peoples R China
[7] Anhui No 2 Prov Peoples Hosp, Dept Cardiol, Hefei 230041, Anhui, Peoples R China
[8] Maanshan Gen Hosp Ranger Duree Healthcare, Dept Cardiol, Maanshan 243071, Anhui, Peoples R China
[9] Anqing Municipal Hosp, Dept Cardiol, Anqing 246004, Anhui, Peoples R China
关键词
heart failure; vericiguat; real-world study;
D O I
10.31083/j.rcm2512427
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Real-world data on the clinical benefit of vericiguat are currently limited. This multicenter, real-world study was conducted to evaluate the clinical characteristics and therapeutic effects of vericiguat in real-world settings.Methods: This study analyzed heart failure (HF) patients who initiated vericiguat treatment from September 2022 to August 2023 across nine hospitals in the Anhui Province, China. The clinical data were retrospectively collected and cases were prospectively followed to assess changes from baseline in N-terminal pro-B type natriuretic peptide (NT-proBNP) at 12 months. Baseline characteristics were compared with those in the VICTORIA trial.Results: Of the 285 patients enrolled, the mean age was 64.8 +/- 12.9 years. Of these, 22.8% were female, and 94.7% were classified as New York Heart Association class III-IV. Additionally, 66.4% had a reduced ejection fraction with a median NT-proBNP level of 2915 pg/mL. Vericiguat therapy was initiated during hospitalization in 223 patients (78.2%), with 105 (37.1%) receiving quadruple anti-HF therapy. Only 44.9% met the VICTORIA trial inclusion criteria.Conclusions: In this multicenter, real-world study of vericiguat in Anhui Province, only 44.9% of vericiguat users met the inclusion criteria for the VICTORIA trial. This suggests that vericiguat is being applied more broadly by physicians to treat HF in real clinical settings.
引用
收藏
页数:7
相关论文
共 22 条
[1]   Empagliflozin in Heart Failure with a Preserved Ejection Fraction [J].
Anker, Stefan D. ;
Butler, Javed ;
Filippatos, Gerasimos ;
Ferreira, Joao P. ;
Bocchi, Edimar ;
Boehm, Michael ;
Brunner-La Rocca, Hans-Peter ;
Choi, Dong-Ju ;
Chopra, Vijay ;
Chuquiure-Valenzuela, Eduardo ;
Giannetti, Nadia ;
Gomez-Mesa, Juan Esteban ;
Janssens, Stefan ;
Januzzi, James L. ;
Gonzalez-Juanatey, Jose R. ;
Merkely, Bela ;
Nicholls, Stephen J. ;
Perrone, Sergio V. ;
Pina, Ileana L. ;
Ponikowski, Piotr ;
Senni, Michele ;
Sim, David ;
Spinar, Jindrich ;
Squire, Iain ;
Taddei, Stefano ;
Tsutsui, Hiroyuki ;
Verma, Subodh ;
Vinereanu, Dragos ;
Zhang, Jian ;
Carson, Peter ;
Lam, Carolyn Su Ping ;
Marx, Nikolaus ;
Zeller, Cordula ;
Sattar, Naveed ;
Jamal, Waheed ;
Schnaidt, Sven ;
Schnee, Janet M. ;
Brueckmann, Martina ;
Pocock, Stuart J. ;
Zannad, Faiez ;
Packer, Milton .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1451-1461
[2]   Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction [J].
Armstrong, Paul W. ;
Pieske, Burkert ;
Anstrom, Kevin J. ;
Ezekowitz, Justin ;
Hernandez, Adrian F. ;
Butler, Javed ;
Lam, Carolyn S. P. ;
Ponikowski, Piotr ;
Voors, Adriaan A. ;
Jia, Gang ;
McNulty, Steven E. ;
Patel, Mahesh J. ;
Roessig, Lothar ;
Koglin, Joerg ;
O'Connor, Christopher M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1883-1893
[3]   A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator The VICTORIA Trial [J].
Armstrong, Paul W. ;
Roessig, Lothar ;
Patel, Mahesh J. ;
Anstrom, Kevin J. ;
Butler, Javed ;
Voors, Adriaan A. ;
Lam, Carolyn S. P. ;
Ponikowski, Piotr ;
Temple, Tracy ;
Pieske, Burkert ;
Ezekowitz, Justin ;
Hernandez, Adrian F. ;
Koglin, Joerg ;
O'Connor, Christopher M. .
JACC-HEART FAILURE, 2018, 6 (02) :96-104
[4]  
Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI [10.1161/CIR.0000000000000659, 10.1161/CIR.0000000000000746]
[5]   Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies [J].
Boettcher, Michael ;
Gerisch, Michael ;
Lobmeyer, Maximilian ;
Besche, Nina ;
Thomas, Dirk ;
Gerrits, Mireille ;
Lemmen, Julia ;
Mueck, Wolfgang ;
Radtke, Martin ;
Becker, Corina .
CLINICAL PHARMACOKINETICS, 2020, 59 (11) :1407-1418
[6]   N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes [J].
Ezekowitz, Justin A. ;
O'Connor, Christopher M. ;
Troughton, Richard W. ;
Alemayehu, Wendimagegn G. ;
Westerhout, Cynthia M. ;
Voors, Adriaan A. ;
Butler, Javed ;
Lam, Carolyn S. P. ;
Ponikowski, Piotr ;
Emdin, Michele ;
Patel, Mahesh J. ;
Pieske, Burkert ;
Roessig, Lothar ;
Hernandez, Adrian F. ;
Armstrong, Paul W. .
JACC-HEART FAILURE, 2020, 8 (11) :931-939
[7]  
Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, 2018, Zhonghua Xin Xue Guan Bing Za Zhi, V46, P760, DOI 10.3760/cma.j.issn.0253-3758.2018.10.004
[8]  
Heidenreich PA, 2022, CIRCULATION, V145, pE895, DOI [10.1161/CIR.0000000000001063, 10.1016/j.jacc.2021.12.011]
[9]   Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States [J].
Khan, Muhammad Shahzeb ;
Xu, Haolin ;
Fonarow, Gregg C. ;
Lautsch, Dominik ;
Hilkert, Robert ;
Allen, Larry A. ;
DeVore, Adam D. ;
Alhanti, Brooke ;
Yancy, Clyde W. ;
Albert, Nancy M. ;
Butler, Javed ;
Greene, Stephen J. .
JACC-HEART FAILURE, 2023, 11 (02) :211-223
[10]   Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial [J].
Lam, Carolyn S. P. ;
Mulder, Hillary ;
Lopatin, Yuri ;
Vazquez-Tanus, Jose B. ;
Siu, David ;
Ezekowitz, Justin ;
Pieske, Burkert ;
O'Connor, Christopher M. ;
Roessig, Lothar ;
Patel, Mahesh J. ;
Anstrom, Kevin J. ;
Hernandez, Adrian F. ;
Armstrong, Paul W. .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (22)